Pharma channel feed – Endpoints News

Pharma channel feed

The 'mind-blowing' R&D renaissance in psychedelic meds finds a home at Johns Hopkins

6 years ago

Mallinckrodt preps a possible bankruptcy amid a maelstrom of opioid claims — report

6 years ago

The pharma industry's rep hits absolute. rock. bottom.

6 years ago

Korean biopharma executive indicted for allegedly conducting illegal trials on company researchers

6 years ago

US judge paves way for branded and generic opioid makers to face landmark October trial

6 years ago

AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study

6 years ago

A new PCSK9 player draws rave reviews for inclisiran. Can a marketing war with Amgen be far behind?

6 years ago

Alexion hit by surprise inter partes review as Amgen challenges Soliris patents

6 years ago

Worst. biotech. deal. ever? Turns out AbbVie has plenty of competition for that title

6 years ago

Mylan wins tentative US approval for generic version of Lilly's Alimta — it could be years before it can be sold

6 years ago

Novartis preps a 2020 launch in multiple sclerosis as 2 successful pivotal trials set stage for an assault on Roche’s new star franchise

6 years ago

EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer

6 years ago

Amgen’s legendary lawyer corps loses a major court fight attempting to quash PCSK9 rival from Sanofi, Regeneron

6 years ago

Tears for FAERS: Another FAERS disaster rumor slams Vertex shares in a Wall Street melee — but this time the tempest passed quickly

6 years ago

Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

6 years ago

Purdue Pharma proposes $12B settlement to clean up opioid mess — report

6 years ago

Decades in the making, Kyowa Hakko Kirin finally wins FDA approval for add-on Parkinson's therapy

6 years ago

Top FDA exec Edward Cox jumps ship and joins Regeneron as new regulatory VP

6 years ago

For sale: Boston Children’s team touts a new CRISPR delivery system for triple-negative breast cancer — plus — after testing it in mice and cells

6 years ago

Oklahoma judge finds J&J guilty for its role in the opioid epidemic — but shares spike on $572M fine

6 years ago

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

6 years ago

Top 20 by revenue: New analysis highlights huge impact of tax reform on many — but not all — of the top pharma giants

6 years ago

Olumiant from Lilly, Incyte clears third eczema study, but who will use it?

6 years ago

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

6 years ago

First page Previous page 263 264 265266267 268 269 Next page Last page